Initially funded through a fee, inclusion as a newborn health benefit by national health insurance (PhilHealth) in 2006 provided the impetus for increases in population coverage for the basic 5-test screening panel (phenylketonuria (PKU), glucose-6-phosphate dehydrogenase (G6PD) deficiency, congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH), and galactosemia (GAL)) [8]. The gene discussed is G6PD; the disease is congenital adrenal hyperplasia.